Lupin receives USFDA nod to market Tamiflu capsules to treat influenza

An employee of Lupin Limited works at a reception at their headquarters in Mumbai
Drug major Lupin on Wednesday said it has received approval from the US Food and Drug Administration (USFDA) to market a generic version of Tamiflu capsules, used in treating influenza.

The company has received final approval from the US drug regulator to market oseltamivir phosphate capsules, a generic version of Hoffman-La Roche Inc's Tamiflu capsules in strengths of 30 mg, 45 mg, and 75 mg, Lupin said in a statement.

Oseltamivir phosphate capsules are indicated for the treatment of influenza.

As per IMS MAT October 2017 data, the capsules clocked annual sales of around $467.8 million in the US market.

Shares of Lupin closed 0.46 per cent up at Rs 925.05 on the BSE.